GlassScriptPhysician profile
Michael D Fugit
NPI 1518917244
$9,013.91
in general payments reported to CMS, 2019-2025
33 companies · $1,059 in 2025
The $1,059 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,925 · 2020: $1,192 · 2021: $1,409 · 2022: $1,389 · 2023: $888 · 2024: $1,152 · 2025: $1,059.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,099.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,098.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $4,374.98 | 2019-2025 | Acticor 7 Vr-T Dx, Biomonitor, Amvia Edge |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,511.47 | 2019-2025 | Lifevest |
| Edwards Lifesciences Corporation | $409.77 | 2019-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Amgen INC. | $378.71 | 2019-2025 | Repatha |
| Catheter Precision, INC. Fka Ra Medical Systems, INC. | $326.82 | 2019 | |
| Sanofi-Aventis U.S. LLC | $293.07 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $263.62 | 2019-2024 | |
| Kestra Medical Technology Services, INC. | $180.81 | 2022-2025 | Assure Wcd |
| Impulse Dynamics (USA) INC. | $178.18 | 2023 | Optimizer |
| Pfizer INC. | $149.68 | 2023-2024 | |
| Heartflow, INC. | $105.94 | 2021-2024 | |
| Siemens Medical Solutions USA, INC. | $103.59 | 2020-2021 | |
| Boston Scientific Corporation | $102.98 | 2022 | |
| Janssen Pharmaceuticals, INC | $100.14 | 2021-2022 | |
| Cordis US Corp. | $94.56 | 2022-2025 | Infiniti |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $62.51 | 2022-2023 | Na |
| Bayer Healthcare Pharmaceuticals INC. | $43.49 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.10 | 2021-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $29.58 | 2022-2023 | Arcalyst |
| Merck Sharp & Dohme LLC | $26.49 | 2024 | Verquvo |
| Medtronic Vascular, INC. | $25.99 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $23.11 | 2022 | |
| Novo Nordisk INC | $21.36 | 2024 | Wegovy |
| W. L. Gore & Associates, INC. | $21.16 | 2022 | |
| Shockwave Medical, INC | $19.89 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Arbor Pharmaceuticals, INC. | $19.80 | 2022 | |
| Medtronic, INC. | $19.11 | 2022 | |
| Alnylam Pharmaceuticals INC. | $17.97 | 2024 | Onpattro |
| Astrazeneca Pharmaceuticals LP | $17.20 | 2023 | Farxiga |
| Azurity Pharmaceuticals, INC. | $16.45 | 2024 | Edarbi |
| Lundbeck LLC | $15.94 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $13.07 | 2022 | |
| Gilead Sciences, INC. | $12.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Fugit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.